[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578174":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":65,"collaborators":25,"id":68,"slug":25,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":25,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":25,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":25,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Miami","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Duloxetine group","EXPERIMENTAL","Participants will be in this group for up to 2 hours.",[13],"Drug: Duloxetine",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo group","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Duloxetine","Participants will come in person and receive a one time 60 mg dose by mouth.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Participants will come in person and receive a one time 60 mg placebo pill dose by mouth.",[15],[31],{"name":32,"affiliation":5,"role":33},"Victor Hernandez, MD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","3056895195","vhh1@miami.edu",{"name":40,"role":36,"phone":37,"phoneExt":25,"email":41},"Natalia Cruz, MD","nxc971@miami.edu",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Miami","Florida","33136","United States",{"type":50,"coordinates":51},"Point",[52,53],-80.19366,25.77427,{"lat":53,"lon":52},[56,57,60,62,64],{"name":40,"role":36,"phone":37,"phoneExt":25,"email":41},{"name":58,"role":36,"phone":37,"phoneExt":25,"email":59},"Ryan Hellinger, BA","rlh147@miami.edu",{"name":61,"role":33,"phone":25,"phoneExt":25,"email":25},"Victor H Hernandez, MD",{"name":40,"role":63,"phone":25,"phoneExt":25,"email":25},"SUB_INVESTIGATOR",{"name":58,"role":63,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Victor Hugo Hernandez","Professor","100578174",false,"NCT06807866","Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT","Use of Duloxetine for Perioperative Pain Control After Total Hip Arthroplasty: Randomized Controlled Clinical Trial (RCT)","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Patients undergoing primary total hip arthroplasty\n* Ambulatory patient prior to fracture\n* Subjects must be capable of providing informed consent\n* English or Spanish speaking\n\nExclusion Criteria:\n\n* Previous hemiarthroplasty or THA on ipsilateral hip\n* History of Complex Regional Pain Syndrome in ipsilateral extremity\n* History of demyelinating disorder or neurologic deficit that may contribute to altered pain tolerance or sensation\n* Acute or chronic hip infection in ipsilateral extremity\n* Pregnant or breastfeeding\n* Open fracture\n* Polytrauma\n* Intravenous or drug users within 6 months of surgery\n* Liver Failure via clinical diagnosis or international normalized ratio greater than 1.5 or partial thromboplastin time greater than 40\n* Patients on selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitor, and\u002For tricyclic anti-depressant\n* Severe renal dysfunctions, such as glomerular filtration rate less than 30\n* Moderate to severe depression as diagnosed by a clinician\n* Taking cytochrome P450 1A2 inhibitors and cytochrome P450 1A6 inhibitors for the duration of 5 half-lives as these drugs are clinically eliminated within 5 half-lives\n* History of uncontrolled narrow angle glaucoma","ALL","18 Years",{"count":77,"type":78},64,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The primary objective of this study is to compare total narcotic intake standardized via milligram morphine equivalents between duloxetine and placebo cohorts after a total hip arthroplasty.",[84],"THA","2026-03-17",{"date":87,"type":88},"2026-03-18","ACTUAL",{"date":90,"type":88},"2025-03-01",{"date":92,"type":78},"2026-12-01",{"name":5,"class":6},1]